Literature DB >> 16672904

Misuse of baseline comparison tests and subgroup analyses in surgical trials.

Mohit Bhandari1, P J Devereaux, Patricia Li, Doug Mah, Ki Lim, Holger J Schünemann, Paul Tornetta.   

Abstract

It is unclear whether the misuse of statistical tests that compare patients' baseline characteristics and subgroup analyses in randomized controlled trials can be extrapolated to the surgical literature. We did an observational study evaluating the current use of baseline comparability tests and subgroup analyses in surgical randomized controlled trials. Published surgical randomized controlled trials in four medical journals were identified. We also identified randomized controlled trials in the Journal of Bone and Joint Surgery (American and British volumes). We identified 72 randomized controlled trials, with a mean of 10 +/- 8 baseline variables. Of 166 significance tests, 17 (10%) were significant. Twenty-seven (38%) trials included 54 subgroup analyses with a minimum of one and maximum of 23 subgroup analyses per study. Inappropriate emphasis on subgroup analyses occurred frequently. Forty-nine (91%) analyses were performed post hoc without prior hypotheses. Investigators reported differences between subgroups in 31 (57%) of the analyses, all of which were featured in the summary or conclusion. These inferences may be misleading, making their application to clinical practice unwarranted.

Entities:  

Mesh:

Year:  2006        PMID: 16672904     DOI: 10.1097/01.blo.0000218736.23506.fe

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  17 in total

1.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

2.  Is a subgroup claim believable? A user's guide to subgroup analyses in the surgical literature.

Authors:  Xin Sun; Diane Heels-Ansdell; Stephen D Walter; Gordon Guyatt; Sheila Sprague; Mohit Bhandari; David Sanders; Emil Schemitsch; Paul Tornetta; Marc Swiontkowski
Journal:  J Bone Joint Surg Am       Date:  2011-02-02       Impact factor: 5.284

Review 3.  Biomarker validation: common data analysis concerns.

Authors:  Joe E Ensor
Journal:  Oncologist       Date:  2014-07-07

4.  Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.

Authors:  Stefan Schandelmaier; Matthias Briel; Ravi Varadhan; Christopher H Schmid; Niveditha Devasenapathy; Rodney A Hayward; Joel Gagnier; Michael Borenstein; Geert J M G van der Heijden; Issa J Dahabreh; Xin Sun; Willi Sauerbrei; Michael Walsh; John P A Ioannidis; Lehana Thabane; Gordon H Guyatt
Journal:  CMAJ       Date:  2020-08-10       Impact factor: 8.262

5.  Baseline matters: the importance of covariation for baseline severity in the analysis of clinical trials.

Authors:  Edward V Nunes; Martina Pavlicova; Mei-Chen Hu; Aimee N Campbell; Gloria Miele; Denise Hien; Donald F Klein
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

6.  The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms.

Authors:  O Naggara; J Raymond; F Guilbert; D G Altman
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

7.  Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials.

Authors:  Xin Sun; Matthias Briel; Jason W Busse; Elie A Akl; John J You; Filip Mejza; Malgorzata Bala; Natalia Diaz-Granados; Dirk Bassler; Dominik Mertz; Sadeesh K Srinathan; Per Olav Vandvik; German Malaga; Mohamed Alshurafa; Philipp Dahm; Pablo Alonso-Coello; Diane M Heels-Ansdell; Neera Bhatnagar; Bradley C Johnston; Li Wang; Stephen D Walter; Douglas G Altman; Gordon H Guyatt
Journal:  Trials       Date:  2009-11-09       Impact factor: 2.279

8.  Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials.

Authors:  William M Reichmann; Michael P LaValley; David R Gagnon; Elena Losina
Journal:  BMC Med Res Methodol       Date:  2013-02-15       Impact factor: 4.615

Review 9.  Reporting characteristics of non-primary publications of results of randomized trials: a cross-sectional review.

Authors:  Sally Hopewell; Gary S Collins; Allison Hirst; Shona Kirtley; Abdelouahid Tajar; Stephen Gerry; Douglas G Altman
Journal:  Trials       Date:  2013-07-31       Impact factor: 2.279

10.  Outcome based subgroup analysis: a neglected concern.

Authors:  Karim F Hirji; Morten W Fagerland
Journal:  Trials       Date:  2009-05-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.